Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CRAXI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.808
EU - Europa 9.157
AS - Asia 3.065
AF - Africa 58
SA - Sud America 49
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 23
Totale 43.184
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.737
IT - Italia 3.093
CN - Cina 2.073
FI - Finlandia 1.538
UA - Ucraina 1.229
IE - Irlanda 777
DE - Germania 647
GB - Regno Unito 582
SG - Singapore 512
RU - Federazione Russa 340
SE - Svezia 312
RO - Romania 179
FR - Francia 149
IN - India 97
KR - Corea 95
BE - Belgio 83
TR - Turchia 83
CA - Canada 53
HK - Hong Kong 51
CH - Svizzera 35
IR - Iran 33
NL - Olanda 33
PL - Polonia 27
CZ - Repubblica Ceca 26
CI - Costa d'Avorio 24
JP - Giappone 24
EG - Egitto 20
AU - Australia 19
EU - Europa 18
BG - Bulgaria 17
AT - Austria 16
BR - Brasile 16
ES - Italia 15
GR - Grecia 15
LB - Libano 15
UZ - Uzbekistan 15
MX - Messico 14
CL - Cile 13
PK - Pakistan 11
VN - Vietnam 10
DK - Danimarca 9
ID - Indonesia 8
PE - Perù 7
PH - Filippine 7
SA - Arabia Saudita 7
PT - Portogallo 6
TW - Taiwan 6
A2 - ???statistics.table.value.countryCode.A2??? 5
HR - Croazia 5
NG - Nigeria 5
CO - Colombia 4
GH - Ghana 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SI - Slovenia 4
VE - Venezuela 4
AR - Argentina 3
IL - Israele 3
LV - Lettonia 3
MY - Malesia 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CU - Cuba 2
EC - Ecuador 2
EE - Estonia 2
IQ - Iraq 2
RS - Serbia 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
CM - Camerun 1
GM - Gambi 1
GT - Guatemala 1
JO - Giordania 1
KH - Cambogia 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
TG - Togo 1
TT - Trinidad e Tobago 1
ZA - Sudafrica 1
Totale 43.184
Salva come PNG Salva come JPEG
Città #
Fairfield 5.454
Ashburn 2.850
Woodbridge 2.682
Chandler 2.177
Wilmington 2.145
Seattle 2.137
Houston 2.083
Cambridge 1.906
Ann Arbor 1.348
Dublin 771
Palermo 755
Medford 728
Jacksonville 649
Altamura 575
Des Moines 516
Nanjing 482
Princeton 460
Lawrence 409
Singapore 384
San Diego 342
Boardman 241
Dearborn 222
Beijing 207
Tulsa 197
New York 162
Shenyang 159
Nanchang 152
Jinan 147
Milan 127
London 121
Hebei 117
Changsha 114
Santa Clara 113
Jiaxing 109
Ludwigshafen am Rhein 95
Tianjin 90
San Paolo di Civitate 88
Seongnam 83
Brussels 80
Zhengzhou 75
Izmir 72
Saint Petersburg 70
Phoenix 69
Ningbo 63
Los Angeles 60
Falls Church 53
Kumar 50
Verona 45
Redwood City 44
Auburn Hills 40
Hangzhou 40
Guangzhou 39
Taizhou 39
Venice 39
Rome 38
Ottawa 36
Helsinki 32
San Mateo 32
Bremen 31
Orange 31
Lanzhou 29
Chicago 27
Kunming 27
Abidjan 24
Munich 24
Kilburn 23
Norwalk 23
Haikou 22
Central 21
Hounslow 20
Redmond 20
Tehran 19
Hong Kong 18
Tappahannock 18
Brno 17
Washington 17
Dallas 16
Düsseldorf 16
Indiana 16
Pune 16
Hefei 15
Taiyuan 15
Chiswick 14
Fuzhou 14
Atlanta 13
Edinburgh 13
Lake Forest 12
Moscow 12
Napoli 12
Berlin 11
Central District 10
Foggia 10
Forest City 10
Islington 10
Prescot 10
Cairo 9
Cuauhtémoc 9
Den Haag 9
Sofia 9
Prineville 8
Totale 33.113
Salva come PNG Salva come JPEG
Nome #
Alexithymia and personality traits of patients with inflammatory bowel disease 234
HCV genotypes in Sicily: is there any evidence of a shift? 233
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 201
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 196
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 193
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 190
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 184
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 181
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 180
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 174
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 174
Clinical course and management of acute and chronic viral hepatitis during pregnancy. 173
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 172
Hepatitis B virus reactivation and alemtuzumab therapy 171
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 170
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 167
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 166
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 165
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 163
Clinical course and genetic susceptibility of primary biliary cirrhosis: Analysis of a prospective cohort 162
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 161
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 158
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. 158
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. 158
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 156
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 155
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 155
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract 155
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response 153
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 152
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 152
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 151
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 150
Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disease 149
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 149
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 149
Primary Biliary Cholangitis: advances in management and treatment of the disease 149
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis 149
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. 149
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis 148
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 148
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 147
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 147
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 147
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 147
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 146
Phylogenetic Reconstruction of HCV Genotype 1b Dissemination in a Small City Centre: The Camporeale Model 146
Clinical trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. 146
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 146
Adefovir for lamivudine resistant HBV: More than meets the eye. 145
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life 144
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 144
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 143
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 143
Management of hepatitis B virus infection in the underprivileged world. 142
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 142
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 141
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 141
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 141
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? 140
Acute hepatitis C: in search of the optimal approach to cure. 139
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 139
Clinical implications of the hyperdynamic syndrome in cirrhosis. 139
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 139
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 138
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 138
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 138
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 137
Characteristics of liver cirrhosis in Italy: results from a multicenter national study 137
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. 136
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 136
Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. 135
Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C 135
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. 135
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 135
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 135
Response to letter from Professor Peter Ferenci 134
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 134
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 134
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 133
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 133
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 133
Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity 132
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 132
Modulation of epitope-specific anti-hepatitis C virus E2(anti-HCV/E2)antibodies by anti-viral treatment 132
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 132
Chronic hepatitis B: who to treat and which choice of treatment? 131
A patient with acute hepatitis C and possible IFN toxicity [2] 131
Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing 131
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 131
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 130
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 130
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 130
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. 130
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 130
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 129
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 129
Fluoroquinolone-induced liver injury: three new cases and a review of the literature. 128
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma 128
Between reality and the guidelines: A survey on perception, diagnosis and management of hepatic encephalopathy in 201 Italian specialist centres 128
Totale 14.927
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.453
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011.165 0 0 787 1.506 1.383 1.620 1.371 942 1.479 654 1.025 398
2020/20216.675 396 618 559 610 494 279 392 485 680 884 621 657
2021/20225.480 273 1.149 159 149 154 230 279 410 687 638 385 967
2022/20236.775 760 1.538 114 651 703 1.050 402 460 686 48 254 109
2023/20242.363 139 418 162 195 197 507 232 139 42 55 18 259
2024/2025791 197 424 170 0 0 0 0 0 0 0 0 0
Totale 44.960